OBJECTIVE: Insufficient data are available on the efficacy of combined conservative interventions recommended by treatment guidelines for knee/hip osteoarthritis (OA). The aims of this observational cohort study were (i) to estimate the results of an evidence-based 12-week tailored multimodal conservative treatment protocol for patients with knee/hip OA and (ii) to identify predictors for response. METHODS: After obtaining data on previous OA-related interventions, multimodal treatment was offered to patients with knee and/or hip OA at a specialized outpatient clinic. Treatment with analgesics was tailored using a numeric rating scale (NRS) for pain, aiming for NRS ≤ 4. The following outcome measures were assessed: (i) the proportion of patients fulfilling OMERACT-OARSI (Outcome Measures in Rheumatoid Arthritis Clinical Trials/Osteoarthritis Research Society International) responder criteria and (ii) the proportion of patients with NRS pain ≤ 4 after 12 weeks. RESULTS: A total of 183 out of 299 patients was included. OMERACT-OARSI responder criteria were fulfilled at 12 weeks in 47% of patients; 39% reached NRS pain ≤ 4. The only independent predictor for response was the number of previously used non-steroidal anti-inflammatory drugs (NSAIDs). The majority of patients had not been exposed adequately to conservative treatment modalities for knee and/or hip OA in the past (81%). CONCLUSION: Evidence-based multimodal conservative treatment using a standardized protocol for knee and/or hip OA is feasible and successful in 47% of patients. In general, response could not be predicted. Basic first-line recommended conservative treatment options have not been used adequately prior to referral to secondary care in the vast majority of patients.
OBJECTIVE: Insufficient data are available on the efficacy of combined conservative interventions recommended by treatment guidelines for knee/hip osteoarthritis (OA). The aims of this observational cohort study were (i) to estimate the results of an evidence-based 12-week tailored multimodal conservative treatment protocol for patients with knee/hip OA and (ii) to identify predictors for response. METHODS: After obtaining data on previous OA-related interventions, multimodal treatment was offered to patients with knee and/or hip OA at a specialized outpatient clinic. Treatment with analgesics was tailored using a numeric rating scale (NRS) for pain, aiming for NRS ≤ 4. The following outcome measures were assessed: (i) the proportion of patients fulfilling OMERACT-OARSI (Outcome Measures in Rheumatoid Arthritis Clinical Trials/Osteoarthritis Research Society International) responder criteria and (ii) the proportion of patients with NRS pain ≤ 4 after 12 weeks. RESULTS: A total of 183 out of 299 patients was included. OMERACT-OARSI responder criteria were fulfilled at 12 weeks in 47% of patients; 39% reached NRS pain ≤ 4. The only independent predictor for response was the number of previously used non-steroidal anti-inflammatory drugs (NSAIDs). The majority of patients had not been exposed adequately to conservative treatment modalities for knee and/or hip OA in the past (81%). CONCLUSION: Evidence-based multimodal conservative treatment using a standardized protocol for knee and/or hip OA is feasible and successful in 47% of patients. In general, response could not be predicted. Basic first-line recommended conservative treatment options have not been used adequately prior to referral to secondary care in the vast majority of patients.
Authors: Agnes J Smink; Cornelia H M van den Ende; Thea P M Vliet Vlieland; Bart A Swierstra; Joke H Kortland; Johannes W J Bijlsma; Theo B Voorn; Henk J Schers; Sita M A Bierma-Zeinstra; Joost Dekker Journal: Clin Rheumatol Date: 2011-09-02 Impact factor: 2.980
Authors: Ellen M H Selten; Rinie Geenen; Henk J Schers; Frank H J van den Hoogen; Roelien G van der Meulen-Dilling; Willemijn H van der Laan; Marc W Nijhof; Cornelia H M van den Ende; Johanna E Vriezekolk Journal: Int J Behav Med Date: 2018-04
Authors: Jesper Knoop; Joyce van Tunen; Martin van der Esch; Leo D Roorda; Joost Dekker; Marike van der Leeden; Willem F Lems Journal: Rheumatol Int Date: 2017-08-18 Impact factor: 2.631
Authors: J B Seeger; J P Schikschneit; C Schuld; R Rupp; S Jäger; H Schmitt; G S Maier; M Clarius Journal: Knee Surg Sports Traumatol Arthrosc Date: 2014-03-27 Impact factor: 4.342
Authors: Veronique M A Voorn; Henricus M Vermeulen; Rob G H H Nelissen; Margreet Kloppenburg; Tom W J Huizinga; Nicolette A C Leijerzapf; Herman M Kroon; Thea P M Vliet Vlieland; Henrica M J van der Linden Journal: Rheumatol Int Date: 2013-01-17 Impact factor: 2.631
Authors: Philip G Conaghan; Paul M Peloso; Sharlette V Everett; Srinivasan Rajagopalan; Christopher M Black; Panagiotis Mavros; Nigel K Arden; Ceri J Phillips; François Rannou; Mart A F J van de Laar; R Andrew Moore; Stephanie D Taylor Journal: Rheumatology (Oxford) Date: 2014-08-23 Impact factor: 7.580
Authors: Agnes J Smink; Sita M A Bierma-Zeinstra; Joost Dekker; Thea P M Vliet Vlieland; Johannes W J Bijlsma; Bart A Swierstra; Joke H Kortland; Theo B Voorn; Cornelia H M van den Ende; Henk J Schers Journal: BMC Fam Pract Date: 2013-03-11 Impact factor: 2.497